文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

基于人工智能的早产儿视网膜病变筛查的成本效益

Cost-effectiveness of Artificial Intelligence-Based Retinopathy of Prematurity Screening.
PubMed 文献 · JAMA Ophthalmol · 2022-01-01

该成本效益分析通过经济建模比较了四种早产儿视网膜病变筛查策略:眼科检查、远程医疗、辅助人工智能加远程医疗复核、自主人工智能仅复核阳性筛查结果。自主人工智能与其它策略同样有效且成本更低;在概率敏感性分析中,自主人工智能在所有支付意愿水平下具有成本效益的概率超过60%。在人工智能灵敏度为99%的模拟队列中,晚期治疗例数从眼科检查的265例降至自主人工智能的40例。

要点

  • 自主人工智能筛查与其它策略同样有效且成本更低。
  • 与远程医疗相比,辅助人工智能和自主人工智能筛查分别在增加成本不超过7美元和34美元时具有成本效益。
  • 与眼科检查相比,辅助人工智能和自主人工智能筛查分别在增加成本不超过64美元和91美元时具有成本效益。

核心结论

  • 基于人工智能的早产儿视网膜病变筛查可能比远程医疗和眼科检查更具成本效益,这取决于人工智能的附加成本以及人工智能与人类检查者检测严重早产儿视网膜病变的相对表现。
  • 随着基于人工智能的早产儿视网膜病变筛查商业化,必须注意为该技术合理定价以确保其效益充分实现。

研究设计与样本

  • 成本效益分析,通过经济建模比较人工智能早产儿视网膜病变筛查与眼科检查及远程医疗。
  • 决策树建模分析了四种早产儿视网膜病变筛查策略:眼科检查、远程医疗、辅助人工智能加远程医疗复核、自主人工智能仅复核阳性筛查结果。
  • 分析了一个每年需要早产儿视网膜病变筛查的美国婴儿理论队列,该队列包括出生孕周30周及以下或出生体重1500克及以下的52000名婴儿。

主要发现

  • 自主人工智能与其它任何筛查策略同样有效且成本更低。
  • 在主要分析中,与远程医疗相比,辅助人工智能和自主人工智能筛查分别在增加成本不超过7美元和34美元时具有成本效益;与眼科检查相比,分别在增加成本不超过64美元和91美元时具有成本效益。
  • 在概率敏感性分析中,自主人工智能筛查在所有支付意愿水平下相对于其它方式具有成本效益的概率超过60%。
  • 在人工智能灵敏度为99%的第二个模拟队列中,早产儿视网膜病变晚期治疗例数从眼科检查筛查的265例降至自主人工智能筛查的40例。

关键数值与推荐

  • 筛查和治疗成本基于现行程序术语编码,并包括医生的估计机会成本。
  • 结局基于早产儿视网膜病变早期治疗研究,定义为及时治疗、晚期治疗或正确未治疗。
  • 增量成本效益比在100000美元支付意愿阈值下计算。
  • 进行了单因素和概率敏感性分析,比较人工智能策略与远程医疗和眼科检查,以评估在一系列假设下的成本效益。
  • 在二次分析中,重复建模并假设人工智能检测严重早产儿视网膜病变的灵敏度高于眼科检查。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Artificial intelligence (AI)-based retinopathy of prematurity (ROP) screening may improve ROP care, but its cost-effectiveness is unknown. OBJECTIVE: To evaluate the relative cost-effectiveness of autonomous and assistive AI-based ROP screening compared with telemedicine and ophthalmoscopic screening over a range of estimated probabilities, costs, and outcomes. DESIGN, SETTING, AND PARTICIPANTS: A cost-effectiveness analysis of AI ROP screening compared with ophthalmoscopy and telemedicine via economic modeling was conducted. Decision trees created and analyzed modeled outcomes and costs of 4 possible ROP screening strategies: ophthalmoscopy, telemedicine, assistive AI with telemedicine review, and autonomous AI with only positive screen results reviewed. A theoretical cohort of infants requiring ROP screening in the United States each year was analyzed. MAIN OUTCOMES AND MEASURES: Screening and treatment costs were based on Current Procedural Terminology codes and included estimated opportunity costs for physicians. Outcomes were based on the Early Treatment of ROP study, defined as timely treatment, late treatment, or correctly untreated. Incremental cost-effectiveness ratios were calculated at a willingness-to-pay threshold of $100 000. One-way and probabilistic sensitivity analyses were performed comparing AI strategies to telemedicine and ophthalmoscopy to evaluate the cost-effectiveness across a range of assumptions. In a secondary analysis, the modeling was repeated and assumed a higher sensitivity for detection of severe ROP using AI compared with ophthalmoscopy. RESULTS: This theoretical cohort included 52 000 infants born 30 weeks' gestation or earlier or weighed 1500 g or less at birth. Autonomous AI was as effective and less costly than any other screening strategy. AI-based ROP screening was cost-effective up to $7 for assistive and $34 for autonomous screening compared with telemedicine and $64 and $91 compared with ophthalmoscopy in the primary analysis. In the probabilistic sensitivity analysis, autonomous AI screening was more than 60% likely to be cost-effective at all willingness-to-pay levels vs other modalities. In a second simulated cohort with 99% sensitivity for AI, the number of late treatments for ROP decreased from 265 when ROP screening was performed with ophthalmoscopy to 40 using autonomous AI. CONCLUSIONS AND RELEVANCE: AI-based screening for ROP may be more cost-effective than telemedicine and ophthalmoscopy, depending on the added cost of AI and the relative performance of AI vs human examiners detecting severe ROP. As AI-based screening for ROP is commercialized, care must be given to appropriately price the technology to ensure its benefits are fully realized.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Morrison SL, Dukhovny D, Chan RVP, et al. Cost-effectiveness of Artificial Intelligence-Based Retinopathy of Prematurity Screening. JAMA Ophthalmol. 2022. PMID: 35297945. doi:10.1001/jamaophthalmol.2022.0223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。